Rhythm is a biopharmaceutical company dedicated to changing how rare genetic disorders of obesity are diagnosed and treated. Disorders of severe obesity may result from genetic variants within the melanocortin-4 receptor (MC4R) pathway, a key pathway responsible for regulating weight, that lead to excessive or insatiable hunger or hyperphagia. Rhythmâs MC4R agonist, setmelanotide, is being evaluated in multiple late-stage clinical studies. The company is also leading efforts to improve patient identification and diagnosis through genetic testing and deepen the communityâs understanding of the ongoing impact and burden of disease on patients and caregivers. Source
No articles found.
Establishment Labs is a global medical technology company focused on improving pat...
Establishment Labs is a global medical technolo...
Dentsply Sirona is the worldâs largest manufacturer of professional dental produ...
Dentsply Sirona is the worldâs largest manufa...
Blueprint Medicines is a precision therapy company striving to improve human healt...
Blueprint Medicines is a precision therapy comp...
Cue Biopharma is an innovative clinical stage immunotherapy company developing a n...
Cue Biopharma is an innovative clinical stage i...
G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on th...
G1 Therapeutics, Inc., is a clinical-stage biop...
Molecular Templates is focused on the discovery, development, and commercializatio...
Molecular Templates is focused on the discovery...
Join the National Investor Network and get the latest information with your interests in mind.